Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9407)	3/29/1999 12:40:00 PM
From: xomadog2	Read Replies (1) \| Respond to of 17367

Blugreen: I believe that the target minimum number of mortality events was established after the first interim. I do not believe it has changed or should have changed. This compound,fortunatley enjoys a subpart E exemption,that gives the FDA latitude in the review process. There was never any secret about the company wanting to have 130 patients in the trial and the FDA requiring 200.There seems to be frustration in your attitude. The minimum number of mortality events has been a requirement of this trial from the point in the trial design that it was set.If you were to have asked the company about this at any time you would have been told the same. I also believe that the rate of accrual will be strong until the end of April this year. It is my opinion that your critique of Xoma and its management should wait until the first week in May before you rush to judgement. If the drug is good and safe one more month wont change whether or not it becomes approved. Will it?